Inositol | myo-Inositol | CAS#6917-35-7 | Insulin Sensitivity | Glucose Disposal

MedKoo Cat#: 540221 | Name: Inositol

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Inositol, also known as myo-Inositol, is an endogenous sugar produced from glucose that is required for production of IMP and phosphatidyl inositol. It is involved in insulin sensitivity and glucose disposal.

Chemical Structure

Inositol

CAS#6917-35-7

Theoretical Analysis

MedKoo Cat#: 540221

Name: Inositol

CAS#: 6917-35-7

Chemical Formula: C6H12O6

Exact Mass: 180.0634

Molecular Weight: 180.15

Elemental Analysis: C, 40.00; H, 6.71; O, 53.28

Price and Availability

Size	Price	Availability	Quantity
10g	USD 250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Inosite, Phaseomannite; myo-Inositol; myoinositol

IUPAC/Chemical Name

cyclohexane-1,2,3,4,5,6-hexaol

InChi Key

CDAISMWEOUEBRE-UHFFFAOYSA-N

InChi Code

InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H

SMILES Code

OC1C(O)C(O)C(O)C(O)C1O

Appearance

White to off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#S7C12T05

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 180.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wilson MS, Livermore TM, Saiardi A. Inositol pyrophosphates: between signalling and metabolism. Biochem J. 2013 Jun 15;452(3):369-79. doi: 10.1042/BJ20130118. Review. PubMed PMID: 23725456. 2: Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol. 2014 Oct;54(10):1079-92. doi: 10.1002/jcph.362. Epub 2014 Jul 18. Review. PubMed PMID: 25042908. 3: Kolozsvari B, Parisi F, Saiardi A. Inositol phosphates induce DAPI fluorescence shift. Biochem J. 2014 Jun 15;460(3):377-85. doi: 10.1042/BJ20140237. PubMed PMID: 24670057. 4: Nagata R, Fujihashi M, Sato T, Atomi H, Miki K. Crystal Structure and Product Analysis of an Archaeal myo-Inositol Kinase Reveal Substrate Recognition Mode and 3-OH Phosphorylation. Biochemistry. 2015 Jun 9;54(22):3494-503. doi: 10.1021/acs.biochem.5b00296. Epub 2015 May 29. PubMed PMID: 25972008. 5: Milewska EM, Czyzyk A, Meczekalski B, Genazzani AD. Inositol and human reproduction. From cellular metabolism to clinical use. Gynecol Endocrinol. 2016 Sep;32(9):690-695. Epub 2016 Sep 5. Review. PubMed PMID: 27595157. 6: Croze ML, Géloën A, Soulage CO. Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation. Br J Nutr. 2015 Jun 28;113(12):1862-75. doi: 10.1017/S000711451500121X. Epub 2015 May 20. PubMed PMID: 25990651. 7: Gurale BP, Sardessai RS, Shashidhar MS. myo-Inositol 1,3-acetals as early intermediates during the synthesis of cyclitol derivatives. Carbohydr Res. 2014 Nov 18;399:8-14. doi: 10.1016/j.carres.2014.08.010. Epub 2014 Aug 23. PubMed PMID: 25216930. 8: Bizzarri M, Fuso A, Dinicola S, Cucina A, Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1181-96. doi: 10.1080/17425255.2016.1206887. Epub 2016 Jul 14. Review. PubMed PMID: 27351907. 9: Greene ND, Leung KY, Gay V, Burren K, Mills K, Chitty LS, Copp AJ. Inositol for the prevention of neural tube defects: a pilot randomised controlled trial. Br J Nutr. 2016 Mar 28;115(6):974-83. doi: 10.1017/S0007114515005322. Epub 2016 Feb 5. PubMed PMID: 26847388; PubMed Central PMCID: PMC4825100. 10: Pazourek J. Fast separation and determination of free myo-inositol by hydrophilic liquid chromatography. Carbohydr Res. 2014 Jun 4;391:55-60. doi: 10.1016/j.carres.2014.03.010. Epub 2014 Mar 20. PubMed PMID: 24785388. 11: Liu J, Zhang N, Liu M. A new inositol triester from Taraxacum mongolicum. Nat Prod Res. 2014;28(7):420-3. doi: 10.1080/14786419.2013.867443. Epub 2014 Jan 16. PubMed PMID: 24432736. 12: Barker CJ, Berggren PO. New horizons in cellular regulation by inositol polyphosphates: insights from the pancreatic β-cell. Pharmacol Rev. 2013 Feb 19;65(2):641-69. doi: 10.1124/pr.112.006775. Print 2013 Apr. Review. PubMed PMID: 23429059. 13: Wu J, Tang C, Yao S, Zhang L, Ke C, Feng L, Lin G, Ye Y. Anti-inflammatory Inositol Derivatives from the Whole Plant of Inula cappa. J Nat Prod. 2015 Oct 23;78(10):2332-8. doi: 10.1021/acs.jnatprod.5b00135. Epub 2015 Oct 7. PubMed PMID: 26444098. 14: Chen W, Deng Z, Chen K, Dou D, Song F, Li L, Xi Z. Synthesis and in vitro anticancer activity evaluation of novel bioreversible phosphate inositol derivatives. Eur J Med Chem. 2015 Mar 26;93:172-81. doi: 10.1016/j.ejmech.2015.01.064. Epub 2015 Feb 9. PubMed PMID: 25681710. 15: Riley AM, Windhorst S, Lin HY, Potter BV. Cellular internalisation of an inositol phosphate visualised by using fluorescent InsP5. Chembiochem. 2014 Jan 3;15(1):57-67. doi: 10.1002/cbic.201300583. Epub 2013 Dec 6. PubMed PMID: 24311195; PubMed Central PMCID: PMC4159588. 16: Lee AM, Painter GF, Compton BJ, Larsen DS. Resolution of orthogonally protected myo-inositols with novozym 435 providing an enantioconvergent pathway to Ac2PIM1. J Org Chem. 2014 Nov 21;79(22):10916-31. doi: 10.1021/jo5019188. Epub 2014 Nov 7. PubMed PMID: 25338261. 17: Godage HY, Riley AM, Woodman TJ, Thomas MP, Mahon MF, Potter BV. Regioselective opening of myo-inositol orthoesters: mechanism and synthetic utility. J Org Chem. 2013 Mar 15;78(6):2275-88. doi: 10.1021/jo3027774. Epub 2013 Mar 5. PubMed PMID: 23438216; PubMed Central PMCID: PMC3601604. 18: Skippen A, Swigart P, Cockcroft S. Measurement of phospholipase C by monitoring inositol phosphates using [³H]inositol labeling protocols in permeabilized cells. Methods Mol Biol. 2013;937:163-74. PubMed PMID: 23007585. 19: Gillaspy GE. The role of phosphoinositides and inositol phosphates in plant cell signaling. Adv Exp Med Biol. 2013;991:141-57. doi: 10.1007/978-94-007-6331-9_8. Review. PubMed PMID: 23775694. 20: Li W, Silipo A, Molinaro A, Yu B. Synthesis of bradyrhizose, a unique inositol-fused monosaccharide relevant to a Nod-factor independent nitrogen fixation. Chem Commun (Camb). 2015 Apr 25;51(32):6964-7. doi: 10.1039/c5cc00752f. Epub 2015 Mar 23. PubMed PMID: 25797311.